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A BS T R AC T
BACKGROUND

The effectiveness of surgery versus observation for men with localized prostate
cancer detected by means of prostate-specific antigen (PSA) testing is not known.
METHODS

From November 1994 through January 2002, we randomly assigned 731 men with
localized prostate cancer (mean age, 67 years; median PSA value, 7.8 ng per milliliter)
to radical prostatectomy or observation and followed them through January 2010.
The primary outcome was all-cause mortality; the secondary outcome was prostatecancer mortality.
RESULTS

During the median follow-up of 10.0 years, 171 of 364 men (47.0%) assigned to radical prostatectomy died, as compared with 183 of 367 (49.9%) assigned to observation
(hazard ratio, 0.88; 95% confidence interval [CI], 0.71 to 1.08; P = 0.22; absolute risk
reduction, 2.9 percentage points). Among men assigned to radical prostatectomy,
21 (5.8%) died from prostate cancer or treatment, as compared with 31 men (8.4%)
assigned to observation (hazard ratio, 0.63; 95% CI, 0.36 to 1.09; P = 0.09; absolute
risk reduction, 2.6 percentage points). The effect of treatment on all-cause and
prostate-cancer mortality did not differ according to age, race, coexisting conditions,
self-reported performance status, or histologic features of the tumor. Radical prostatectomy was associated with reduced all-cause mortality among men with a PSA
value greater than 10 ng per milliliter (P = 0.04 for interaction) and possibly among
those with intermediate-risk or high-risk tumors (P = 0.07 for interaction). Adverse
events within 30 days after surgery occurred in 21.4% of men, including one death.
CONCLUSIONS

Among men with localized prostate cancer detected during the early era of PSA testing, radical prostatectomy did not significantly reduce all-cause or prostate-cancer
mortality, as compared with observation, through at least 12 years of follow-up.
Absolute differences were less than 3 percentage points. (Funded by the Department
of Veterans Affairs Cooperative Studies Program and others; PIVOT ClinicalTrials
.gov number, NCT00007644.)
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he treatment of early-stage prostate cancer remains controversial, especially
for tumors detected by means of prostatespecific antigen (PSA) testing.1 Systematic reviews
have provided inadequate information for assessing the comparative effectiveness of treatments
and any associated harms.2 Although the lifetime
risk of receiving a diagnosis of prostate cancer is
about 17%, the risk of dying from the disease is
approximately 3%, suggesting that conservative
management may be appropriate for many men.3,4
Two randomized trials compared radical prostatectomy with observation but were conducted
before PSA testing became widespread.5,6 One
study failed to show a significant difference in
overall mortality after more than 20 years.5 Another showed absolute differences in all-cause and
prostate-cancer mortality at 15 years of 6.6 percentage points and 6.1 percentage points, respectively, in favor of surgery.6 Benefits were confined
to men younger than 65 years of age. A randomized trial comparing external-beam radiotherapy
with observation, also among men who received
the diagnosis before PSA testing became widespread, showed no significant differences in mortality through at least 16 years.7 During the era of
PSA testing, an observational study showed high
10-year survival rates among men treated conservatively.8 Despite excellent long-term, disease-specific survival with observation, this option is rarely
used, in part because of a lack of evidence from
randomized trials comparing observation with attempted curative treatment for prostate cancer detected since PSA testing became common practice. We conducted a randomized trial to compare
radical prostatectomy with observation in 731 men
who had received a diagnosis of clinically localized
prostate cancer in the early era of PSA testing.

ME THODS
STUDY DESIGN

We previously reported the baseline characteristics of the patients and the design of the Prostate
Cancer Intervention versus Observation Trial
(PIVOT).9 Enrollment began in November 1994
and ended in January 2002, with follow-up
through January 2010. We recruited men from 44
Department of Veterans Affairs sites and 8 National Cancer Institute sites.
The research protocol was approved by the institutional review board at each site. All patients
204
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provided written informed consent. Randomization was stratified according to site and implemented by means of a central interactive telephone
system.
Patients had to be medically fit for radical
prostatectomy and to have histologically confirmed, clinically localized prostate cancer (stage
T1-T2NxM0 in the tumor–node–metastasis classification system according to the American Joint
Committee on Cancer10) of any grade diagnosed
within the previous 12 months. Patients also had
to have a PSA value of less than 50 ng per milli
liter, an age of 75 years or less, negative results
on a bone scan for metastatic disease, and a life
expectancy of at least 10 years from the time of
randomization. The study sites assessed eligibility on the basis of locally obtained PSA values and
biopsy readings. After randomization, a central
pathologist reviewed the biopsy and radical-prostatectomy specimens, and a central laboratory
measured PSA.
TREATMENT PROTOCOL

The technique used for radical prostatectomy was
at the surgeon’s discretion. Additional interventions were determined by each participant and his
physician. Men randomly assigned to the observation group were offered palliative therapy or chemotherapy for symptomatic or metastatic progression.
FOLLOW-UP AND CLINICAL OUTCOMES

We scheduled study visits every 6 months for a
minimum of 8 years and a maximum of 15 years
or until the patient died. Bone scans were obtained at 5, 10, and 15 years or at the last visit for
persons with less than 15 years of follow-up,
with additional scans obtained at the clinician’s
discretion. The primary outcome was all-cause
mortality. Our secondary outcome was prostatecancer mortality, which was defined as death that
was definitely or probably due to prostate cancer
or definitely or probably due to prostate-cancer
treatment by a three-member end-points committee that was unaware of the study assignments.
Bone metastases were documented on the basis of
positive results of bone scanning or skeletal radiography. We assessed 30-day perioperative harms
and the prevalence of urinary incontinence and
erectile and bowel dysfunction at 2 years, which
was based on self-reported dysfunction that was
at least moderate in severity.

nejm.org

july 19, 2012

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on April 29, 2014. For personal use only. No other uses without permission.
Copyright © 2012 Massachusetts Medical Society. All rights reserved.

Treatment or Observation for Localized Prostate Cancer

STUDY OVERSIGHT

The authors are responsible for the study design
and oversight and the analysis and reporting of the
data. All authors vouch for the accuracy of the data
and the fidelity of the study to the protocol. The
site investigators and assistants collected and transmitted data to the coordinating center for analysis. An independent data and safety monitoring
board monitored the trial for safety and scientific
integrity. Interim analyses were stipulated in the
protocol.
STATISTICAL ANALYSIS

We carried out analyses according to the intentionto-treat principle. Recruitment difficulties prevented the attainment of our original goal of enrolling 2000 men. We revised our sample on the
basis of estimates that 740 men enrolled over a
period of 7 years, with an additional 8 years of
follow-up, would provide 91% power to detect a
25% relative reduction in all-cause mortality, assuming a median survival of 10 years. The data and
safety monitoring board reviewed and approved
this revision. For assessment of the secondary end
point (death from prostate cancer or treatment), a
survival analysis was performed in which the data
from surviving patients were censored at the end
of the study and the data from patients who died
from causes other than prostate cancer were censored at the date of death from that other cause.11
We analyzed death from any cause, death from
prostate cancer (with death from other causes
treated as a competing risk), and bone metastases. Outcomes were analyzed with the use of a
proportional-hazards model, which provided hazard ratios and corresponding 95% confidence intervals. Cumulative incidence and between-group
differences were assessed at 4, 8, and 12 years
and at the end of the study. P values of less than
0.05 (two-sided) were considered to indicate statistical significance.
Mortality and bone metastases were estimated
for each study group with the Kaplan–Meier
method. Seven subgroups defined according to
baseline characteristics were prespecified for assessment of overall and prostate-cancer mortality
and were specified post hoc for assessment of bone
metastases: age (<65 years vs. ≥65 years), race
(white, black, or other), coexisting conditions
(Charlson comorbidity index score, 0 vs. ≥1),12
self-reported performance status (0 [fully active]
vs. 1 to 4, with higher scores indicating poorer
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functional status), PSA level (≤10 vs. >10 ng per
milliliter), score on the Gleason histologic scale
(<7 vs. ≥7 on a scale of 2 to 10, with 10 indicating the most poorly differentiated tumors),10,13 and
D’Amico tumor risk score (low, intermediate, or
high), which was based on tumor stage, the histologic score assigned by the local study site, and
the PSA level.14
To determine whether the treatment effect varied according to subgroup, we performed tests of
interaction between group assignment and riskfactor category. Modification of the effect of radical prostatectomy according to subgroup was assessed by means of a Cox proportional-hazards
model that included an interaction term between
subgroup category and study group. A P value of
less than 0.05 was considered to indicate statistical significance, with no correction for multiple
comparisons. We performed sensitivity analyses
using centrally assessed histopathological findings
and PSA values. We used SAS software, version 9.2
(SAS Institute), for all analyses.11 The protocol,
including the statistical analysis plan, is available
with the full text of this article at NEJM.org.

R E SULT S
CHARACTERISTICS OF THE PARTICIPANTS

Among 13,022 men with prostate cancer (Fig. 1),
5023 were eligible for enrollment. A total of 731
men (14.6%) agreed to participate and underwent
randomization to radical prostatectomy (364 men)
or observation (367). The mean age was 67 years
(see Table 1 in the Supplementary Appendix, available at NEJM.org). Nearly one third of the patients
were black; 85% reported full independence in
activities of daily living. The median PSA value was
7.8 ng per milliliter (mean, 10.1). About 50% of
the men had stage T1c disease (not palpable, detected by means of PSA testing), and about 25%
had histologic scores of 7 or higher on the Gleason
scale; 40% of the men had low-risk, 34% intermediate-risk, and 21% high-risk prostate cancer
(about 5% had missing data). On the basis of
central pathological review, 48% of the patients
had histologic scores of 7 or higher on the Gleason
scale, and 66% had tumors in the intermediaterisk or high-risk categories.
TREATMENT ADHERENCE

During follow-up, 287 of the 364 men (78.8%) who
were randomly assigned to radical prostatectomy
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(38.4%) (Table 2 in the Supplementary Appendix).
On the basis of local pathological findings, the
tumor was confined to the prostate in 150 men
(53.4%), including 65.8% of those with low-risk
prostate cancer (75 of 114 men) and 35.6% of
those with high-risk disease (21 of 59). Capsular
invasion was noted in 28 men (10.0%) and capsular penetration in 16 (5.7%). Surgical margins were
positive for tumor in 64 men (22.8%).

13,022 Men with newly diagnosed prostate
cancer entered into screening registry

5023 Were eligible

4292 Declined to participate

ALL-CAUSE MORTALITY
731 Underwent randomization

364 Were assigned to radical-prostatectomy group
281 Underwent radical prostatectomy
53 Underwent observation
6 Underwent attempted radical
prostatectomy but incomplete
owing to positive lymph nodes
14 Underwent EBRT
9 Underwent brachytherapy
1 Underwent unspecified irradiation

367 Were assigned to observation group
292 Underwent observation
36 Underwent radical prostatectomy
1 Underwent attempted radical
prostatectomy but incomplete
29 Underwent EBRT
8 Underwent brachytherapy
1 Underwent cryotherapy

Figure 1. Study Enrollment and Treatment.
Of a total of 13,022 men who were screened for participation, 5023 were
eligible for enrollment; of these, 731 were randomly assigned to radical
prostatectomy or observation. Of the 364 men in the radical-prostatectomy
group, 287 underwent attempted surgery, as did 37 of the 367 men in the
observation group. EBRT denotes external-beam radiotherapy.

underwent an attempted radical prostatectomy
(median time from randomization to surgery, 35
days; interquartile range, 24 to 50), and 311 (85.4%)
received definitive therapy (median time from randomization to definitive therapy, 36 days; interquartile range, 24 to 59). Among men assigned to
the observation group, 37 (10.1%) underwent an attempted radical prostatectomy (median time from
randomization to surgery, 61 days; interquartile
range, 30 to 624) (Fig. 1), and 75 (20.4%) received
definitive therapy (median time from randomization to initiation of treatment, 652 days; interquartile range, 61 to 1502). Median follow-up from
randomization until death or the end of the study
was 10.0 years (interquartile range, 7.3 to 12.6).

By the end of the study, 354 men (48.4%) had died
(Table 3 in the Supplementary Appendix). Among
men in the radical-prostatectomy group, 171
(47.0%) died, as compared with 183 (49.9%) in the
observation group (hazard ratio, 0.88; 95% confidence interval [CI], 0.71 to 1.08; P = 0.22; absolute
risk reduction, 2.9 percentage points; 95% CI,
−4.1 to 10.3) (Fig. 2A, and Table 4 in the Supplementary Appendix).
Median survival was 13.0 years (95% CI, 12.2
to 13.7) in the radical-prostatectomy group and
12.4 years (95% CI, 11.4 to 13.1) in the observation group. At 12 years, 40.9% of men assigned
to radical prostatectomy and 43.9% of those assigned to observation had died. The absolute reduction in mortality with radical prostatectomy
was not significant at any interval and declined
over time, from 4.6 percentage points (95% CI,
−0.2 to 9.3) at 4 years to 2.9 percentage points
(95% CI, −4.2 to 10.0) at 12 years.
PROSTATE-CANCER MORTALITY

Death attributed to prostate cancer or treatment
occurred in 52 men (7.1%) (Table 3 in the Supplementary Appendix). In the radical-prostatectomy
group, 21 of 364 men (5.8%) died from prostate
cancer or treatment, as compared with 31 of 367
(8.4%) in the observation group (hazard ratio, 0.63;
95% CI, 0.36 to 1.09; P = 0.09; absolute risk reduction, 2.6 percentage points; 95% CI, −1.1 to 6.5)
(Fig. 2B). Two thirds of the deaths due to prostate
cancer (34 of 52 deaths, accounting for 4.7% of all
patients) were considered to be definitely due to
prostate cancer or treatment, with no significant
difference between the groups: 16 men (4.4%) in
the radical-prostatectomy group and 18 (4.9%) in
SURGICAL TECHNIQUE AND PATHOLOGICAL
the observation group. Prostate-cancer mortality
FINDINGS
was identical in the observation and radical-prosOf the 281 radical-prostatectomy procedures per- tatectomy groups at 4 years. At 12 years, radical
formed in men in the radical-prostatectomy group prostatectomy was associated with a nonsignifi(Fig. 1), nerve-sparing surgery was used in 108 cant absolute reduction in mortality of 3.0 per206
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A Death from Any Cause
1.0

Proportion Who Died

centage points, as compared with observation
(4.4 vs. 7.4 percentage points; relative risk, 0.60;
95% CI, 0.33 to 1.09), declining slightly at the
end of the study (Fig. 2B, and Table 5 in the Supplementary Appendix).
BONE METASTASES

SUBGROUP AND SENSITIVITY ANALYSES

All-Cause Mortality

The effect of radical prostatectomy, as compared
with observation, on all-cause mortality did not
differ significantly according to age, score on the
Gleason histologic scale, race, self-reported performance status, or score on the Charlson comorbidity index. We identified a significant interaction
between study group and baseline PSA value
(P = 0.04 for interaction) and a borderline interaction (P = 0.07) for tumor risk category (Fig. 3A,
and Table 3 in the Supplementary Appendix). As
compared with observation, surgery did not reduce all-cause mortality among men with a PSA
value of 10 ng per milliliter or less (median, 6.0)
(hazard ratio, 1.03; 95% CI, 0.79 to 1.35). Among
men with a PSA value greater than 10 ng per milliliter (median, 15.0), surgery reduced all-cause
mortality by 13.2% (hazard ratio, 0.67; 95% CI,
0.48 to 0.94) (Fig. 2A and 2B and Table 4 in the
Supplementary Appendix).
Among men with intermediate-risk tumors (as
determined by a PSA value of 10.1 to 20.0 ng per
milliliter, a score of 7 on the Gleason scale, or a
stage T2b tumor), those who were randomly assigned to surgery had a 31% relative reduction in
all-cause mortality, as compared with those assigned to observation (hazard ratio, 0.69; 95% CI,
0.49 to 0.98; absolute risk reduction, 12.6 percentage points). Among men with high-risk tumors,
surgery resulted in a nonsignificant absolute
reduction in mortality of 6.7 percentage points,
as compared with observation (P = 0.16) (Fig. 2C,
2D, and 2E in the Supplementary Appendix). In
contrast, among men with low-risk cancers (as
determined by a PSA value ≤10 ng per milliliter,
n engl j med 367;3
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Bone metastases occurred in 17 men assigned to
radical prostatectomy (4.7%), as compared with 39
(10.6%) assigned to observation (hazard ratio, 0.40;
95% CI, 0.22 to 0.70; P<0.001) (Fig. 1 and Table 6
in the Supplementary Appendix). Differences in the
cumulative incidence between the radical-prostatectomy and observation groups changed little after 8 years of follow-up.
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Figure 2. Kaplan–Meier Plots of Mortality.
By the end of the study, 354 men (48.4%) had died from any cause (Panel A).
Death attributed to prostate cancer or treatment occurred in 52 men (7.1%)
(Panel B). Data from the radical-prostatectomy group are shown in red, and
data from the observation group in blue.

a score of 6 or less on the Gleason scale, and a
stage T1a–c or T2a tumor), there was a 15% nonsignificant increase in mortality among men randomly assigned to radical prostatectomy, as compared with those assigned to observation (hazard
ratio, 1.15; 95% CI, 0.80 to 1.66). The absolute
difference at 12 years was 5.4 percentage points,
in favor of observation over surgery (37.2% vs.
31.8%). Sensitivity analyses performed with the
use of central biopsy readings showed no significant differences in all-cause mortality between
radical prostatectomy and observation according
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A Death from Any Cause
Subgroup
Overall
Age
<65 yr
≥65 yr
Race
White
Black
Other
Charlson score
0
≥1
Performance score
0
1–4
PSA
≤10
>10
Risk
Low
Intermediate
High
Gleason score
<7
≥7

Observation

Radical
Prostatectomy

P Value for
Interaction

Hazard Ratio (95% CI)

no. of events/total no.
183/367
171/364

0.88 (0.71–1.08)

50/131
133/236

43/122
128/242

0.89 (0.59–1.34)
0.84 (0.63–1.08)

119/220
53/121
11/26

117/232
46/111
8/21

0.84 (0.65–1.08)
0.93 (0.62–1.38)
0.85 (0.34–2.11)

86/220
97/147

82/224
89/140

0.90 (0.66–1.21)
0.84 (0.63–1.13)

146/310
37/57

139/312
32/52

0.89 (0.71–1.13)
0.82 (0.51–1.31)

101/241
77/125

110/238
61/126

1.03 (0.79–1.35)
0.67 (0.48–0.94)

54/148
70/120
49/80

62/148
59/129
42/77

1.15 (0.80–1.66)
0.69 (0.49–0.98)
0.74 (0.49–1.13)

125/261
47/86

113/254
50/98

0.86 (0.67–1.12)
0.84 (0.56–1.25)

0.85

0.81

0.79

0.66

0.04

0.07

0.87

0.14

0.37

1.00

2.72

Radical Prostatectomy Observation
Better
Better

B Death from Prostate Cancer
Subgroup
Overall
Age
<65 yr
≥65 yr
Race
White
Black
Other
Charlson score
0
≥1
Performance score
0
1–4
PSA
≤10
>10
Risk
Low
Intermediate
High
Gleason score
<7
≥7

Observation

Radical
Prostatectomy

no. of events/total no.
31/367
21/364

0.63 (0.36–1.09)

12/131
19/236

6/122
15/242

0.52 (0.20–1.39)
0.68 (0.34–1.33)

22/220
7/121
2/26

15/232
5/111
1/21

0.57 (0.30–1.10)
0.80 (0.25–2.54)
0.56 (0.05–6.17)

19/220
12/147

14/224
7/140

0.69 (0.34–1.37)
0.54 (0.21–1.38)

25/310
6/57

18/312
3/52

0.67 (0.37–1.23)
0.41 (0.10–1.71)

15/241
16/125

14/238
7/126

0.92 (0.44–1.91)
0.36 (0.15–0.89)

4/148
13/120
14/80

6/148
6/129
7/77

1.48 (0.42–5.24)
0.50 (0.21–1.21)
0.40 (0.16–1.00)

15/261
15/86

11/254
10/98

0.68 (0.31–1.49)
0.51 (0.23–1.14)

0.63

0.76

0.63

0.57

0.11

0.11

0.57

0.05

0.14

0.37

1.00

Radical Prostatectomy
Better

208

P Value for
Interaction

Hazard Ratio (95% CI)
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PSA level of 10 ng per milliliter or less (P = 0.82) or
among those with low-risk tumors (P = 0.54) or intermediate-risk tumors (P = 0.12) (Fig. 3A through
3E and Table 5 in the Supplementary Appendix).
The results for prostate-cancer mortality were
generally consistent when we substituted central
for local PSA measures and histopathological findings. However, among men with intermediaterisk prostate cancer, the absolute risk difference
of 4.6 percentage points in favor of radical prostatectomy on the basis of local histologic findings
changed to 1.3 percentage points in favor of observation, on the basis of central histologic findings. Bone metastases were not reduced among
men with PSA values of 10 ng per milliliter or less
or among those with low-risk disease. Among
men with PSA levels that were greater than 10 ng
per milliliter or with intermediate-risk or highrisk disease, absolute reductions of approximately
9.0 to 11.0 percentage points occurred. Subgroup
differences in cumulative incidence remained stato scores on the Gleason scale or tumor risk ble after about 8 years (Table 6 in the Supplemencategories (P>0.13 for all categories). When local tary Appendix).
histologic findings for men with intermediaterisk disease and those with high-risk disease were SURGICAL MORBIDITY
pooled, radical prostatectomy was associated with Perioperative complications during the first 30 days
an absolute reduction in all-cause mortality of after surgery occurred in 21.4% of men in the
10.5 percentage points (hazard ratio, 0.71; 95% radical-prostatectomy group who underwent radCI, 0.54 to 0.92; P = 0.01). The reduction in mor- ical prostatectomy and included one death. The
tality was smaller and was not significant when most common complication was wound infecthe pooled data were assessed on the basis of tion, in 4.3% of the men (Table 1). Complications
central pathological review (hazard ratio, 0.81; occurring in more than 2% of the men included
95% CI, 0.63 to 1.0; P = 0.10; absolute risk reduc- urinary tract infection, surgical repair, bleeding
tion, 4.7 percentage points).
requiring transfusion, and urinary catheterization
more than 30 days after surgery. At 2 years, paProstate-Cancer Mortality
tient-reported urinary incontinence and erectile
As compared with observation, the effect of radi- dysfunction, but not bowel dysfunction, were sigcal prostatectomy on prostate-cancer mortality did nificantly more common among men who were
not differ significantly according to age, race, randomly assigned to radical prostatectomy than
score on the Charlson comorbidity index, or self- among those randomly assigned to observation
reported performance status (Fig. 3B). We found (Table 2).
some evidence of treatment interaction for subgroups defined by PSA value and tumor risk catDiscussion
egory (P = 0.11 for interaction for both comparisons). Prostate-cancer mortality was lower in the Among men with clinically localized prostate
radical-prostatectomy group than in the observa- cancer that had been diagnosed after PSA testing
tion group among men with a PSA value of more came into practice, our study showed that radical
than 10 ng per milliliter (5.6% vs. 12.8%, P = 0.02) prostatectomy did not reduce all-cause or prostateand among men with high-risk prostate cancer cancer mortality, as compared with observation,
(9.1% vs. 17.5%, P = 0.04). However, prostate-can- through at least 12 years of follow-up. Confidence
cer mortality was not significantly lower in the intervals for the effect size indicated that surgery
radical-prostatectomy group among men with a did not reduce all-cause mortality by more than
Figure 3 (facing page). Forest Plots for Primary
and Secondary Outcomes.
There were no significant between-group differences in
all-cause mortality according to age, score on the Gleason histologic scale (<7 vs. ≥7 on a scale of 2 to 10, with
10 indicating the most poorly differentiated tumors),13
self-reported race, self-reported performance status
(0 [fully active] vs. 1 to 4, with higher scores indicating
poorer functional status), or score on the Charlson comorbidity index12 (Panel A), but there was a significant
interaction between study group and baseline PSA value
(P = 0.04 for interaction) and a borderline interaction
(P = 0.07) for tumor risk (D’Amico tumor risk score
[low, intermediate, or high], which was based on tumor
stage, histologic score, and PSA level14). Prostate-cancer
mortality did not differ significantly between the study
groups according to age, race, score on the Charlson
comorbidity index, or self-reported performance status
(Panel B), although there was borderline evidence of
an interaction for PSA value and tumor-risk category
(P = 0.11 for interaction for both comparisons). The bars
indicate 95% confidence intervals, and the size of the
symbol indicates the weight of the estimate.
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Table 1. Adverse Events Occurring within 30 Days
after Surgery.*
Event

Patients
(N = 280)

Any

60 (21.4)

no. (%)
Pneumonia

2 (0.7)

Wound infection

12 (4.3)

Urinary tract infection

7 (2.5)

Sepsis

3 (1.1)

Deep-vein thrombosis

2 (0.7)

Stroke

1 (0.4)

Pulmonary embolism

2 (0.7)

Myocardial infarction

3 (1.1)

Renal failure or dialysis

1 (0.4)

Bowel injury requiring surgical repair

3 (1.1)

Additional surgical repair

7 (2.5)

Bleeding requiring transfusion

6 (2.1)

Urinary catheter present >30 days
after surgery

6 (2.1)

Death

1 (0.4)

Other

28 (10.0)

* Of the 364 men randomly assigned to the radical-prostatectomy group, radical prostatectomy was completed in
280. Multiple events may have occurred in a single patient.

10% and might have increased mortality by as
much as 4%. Differences in all-cause mortality decreased over time, suggesting that longer followup would not alter these findings. Only 10% of
patients were younger than 60 years of age. Longer follow-up may be important for the minority
of men with prostate cancer who were younger
than 60 years of age. However, the nonsignificant
between-group difference in prostate-cancer mortality and the significant 6% reduction in bone
metastases with radical prostatectomy remained
fairly constant after 8 years. Our findings add to
evidence supporting observation, and possibly active surveillance, for most men who receive a diagnosis of localized prostate cancer, especially those
with a low PSA value or low-risk disease.2,3,6,8,15-24
Death due to prostate cancer or treatment occurred infrequently, in 7.1% of patients. Any differences in prostate-cancer mortality between surgery and observation occurred primarily among
men whose death was judged as probably due to
prostate cancer or treatment. Among men whose
210
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death was considered to be definitely due to prostate cancer or treatment, we found almost no difference between surgery and observation. Between-group differences in the time of death due
to prostate cancer or treatment did not explain
the differences in all-cause mortality in the entire
cohort or the subgroups. These findings highlight the limitations of using prostate-cancer
mortality as an outcome, even with the use of adjudication committees whose members are unaware of treatment assignments and who are following standardized protocols.25-27
The effect of radical prostatectomy on mortality did not vary according to age, race, self-reported performance status, or coexisting conditions,
but our findings suggest that it may vary according to PSA value and possibly tumor risk. Positive
results were from multiple subgroup comparisons; the tests of interaction typically approached
but did not reach significance and may therefore
be due to chance. Among men with PSA levels of
10 ng per milliliter or less, all-cause mortality was
slightly lower at 12 years in the observation group
than in the radical-prostatectomy group; prostatecancer mortality in the observation group was
6%, with a nonsignificant absolute reduction of
less than 1.0 percentage point in the radicalprostatectomy group. Among men with low-risk
disease, observation was associated with a nonsignificant reduction in all-cause and prostate
cancer mortality, with no significant betweengroup difference in bone metastases. Among men
with a PSA value that was greater than 10 ng per
milliliter and possibly among those with intermediate-risk or high-risk prostate cancer (as determined according to the PSA value, local histologic findings, and stage), absolute reductions in
all-cause mortality with radical prostatectomy
ranged from 6.7 to 13.2 percentage points. Reductions were smaller and not significant when
central histopathological findings were used, and
we found no significant reductions with radical
prostatectomy in categories that were derived
solely on the basis of higher scores on the Gleason
histologic scale or tumor stage. Reductions in
prostate-cancer mortality in the radical-prostatectomy group were limited to men with a PSA
value that was greater than 10 ng per milliliter and
to those with high-risk disease, with absolute
reductions of 7.2 to 8.4 percentage points. Absolute reductions in bone metastases of 10.4 and
8.6 percentage points occurred, respectively, in
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men with a PSA value of 10 ng per milliliter or
higher and in those with high-risk disease.
As compared with the Scandinavian Prostate
Cancer Group 4 (SPCG-4) trial of radical prostatectomy versus watchful waiting in men with prostate cancer detected before widespread PSA testing,6 PIVOT enrolled a higher percentage of men
with nonpalpable tumors (stage T1c, 50% vs. 12%)
and with PSA values of 10 ng per milliliter or
lower. Treatment adherence was similar in the
two trials.6,28 In contrast to the SPCG-4 trial, we
did not find a significant reduction in all-cause
or prostate-cancer mortality with radical prostatectomy. Our findings are particularly robust among
men with a PSA value of 10 ng per milliliter or
less, including men with a score of 7 or higher on
the Gleason histologic scale, and low-risk tumor
— categories that were underrepresented in the
SPCG-4 trial. Unlike the SPCG-4 trial, our study
did not show that the effect of surgery, as compared with observation, varied according to age.
Although hazard ratios indicated that the relative
effect of radical prostatectomy on prostate-cancer
mortality was similar in PIVOT and the SPCG-4
trial (37% and 38% reduction, respectively), the
relative reduction in all-cause mortality in our
study was less than half that in the SPCG-4 trial
(12% vs. 25%), as were the absolute reductions
in all-cause mortality (2.9 percentage points vs.
6.6 percentage points) and prostate-cancer mortality (2.6 percentage points vs. 6.1 percentage
points); the overall percentage of men who died
from prostate cancer was also lower in our study
(7.1% vs. 19.6%). The mortality reductions in our
study were not significant and probably reflect
the more favorable prognosis for patients with
tumors detected by means of PSA testing.
Our study has strengths that enhance the clinical applicability of the findings. The age, health
status, PSA value, and tumor-risk characteristics of
the men enrolled in this study were similar to
those of both men who were eligible but declined
to undergo randomization9 and men in the general population who have received a diagnosis of
prostate cancer.1-3,8,29 Perioperative morbidity and
mortality were similar to those previously reported.28,30 The percentage of men with positive surgical margins was similar to that in earlier studies
and lower than that in the SPCG-4 trial.27 The tumor volumes and PSA values in our study population, although higher than in some contemporary
series,31-35 are probably representative of those in
n engl j med 367;3

Table 2. Patient-Reported Urinary, Erectile, and Bowel Dysfunction at 2 Years,
According to Study Group.*
Dysfunction

Radical
Prostatectomy

Observation

P Value

no./total no. (%)
Urinary incontinence†

49/287 (17.1)

18/284 (6.3)

<0.001

Erectile dysfunction‡

231/285 (81.1)

124/281 (44.1)

<0.001

35/286 (12.2)

32/282 (11.3)

0.74

Bowel dysfunction§

* The values reported are the number of men reporting the dysfunction and the
total number of men who responded to the question.
† Urinary incontinence was defined by patient reports (“have a lot of problems with
urinary dribbling,” “lose larger amounts of urine than dribbling but not all
day,” “have no control over urine,” or “have an indwelling catheter”).
‡ Erectile dysfunction was defined as the inability to have an erection or an
erection sufficient for vaginal penetration.
§ Bowel dysfunction was defined by patient reports that it was a “moderate” or
“big” problem.

the general population of men who received a diagnosis of prostate cancer at the time the study
was being conducted. Our choice of all-cause mortality as the primary outcome underscores the
importance of improving life expectancy with cancer treatment and eliminates the possibility of biased cause-of-death ascertainment.25-27
Our study was conducted in the early era of
PSA testing. The current practices of performing
repeated PSA testing, using a lower PSA threshold for biopsy, obtaining more tissue-biopsy cores,
and performing a repeat biopsy after initially negative findings increase the detection of smallervolume indolent cancers.15,16 Along with systematically higher assignment of tumor grades
(upgrading), these factors increase the likelihood
of overdiagnosis and overtreatment.36-38 Among
men with a current diagnosis of prostate cancer
who undergo radical prostatectomy, the absolute
reductions in the risks of metastasis and death will
probably be smaller, and the time required to
identify a reduction will probably be longer than
reported in our study or in the SPCG-4 trial.
Our findings support observation for men with
localized prostate cancer, especially those who
have a low PSA value and those who have low-risk
disease. Up to two thirds of men who have received a diagnosis of prostate cancer have a low
PSA value or low-risk disease, but nearly 90% receive early intervention — typically surgery or radiotherapy.1,15,16,24 In contrast to observation, active surveillance initiates therapy with curative
intent if disease progression is suspected on the
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basis of repeat PSA testing, digital rectal examinations, and prostate biopsies.3,24 Active surveillance
is being compared with surgery or radiotherapy
in a randomized trial.39 Informing men of the favorable long-term effects of observation on mortality, bone metastases, urinary and erectile function,
and quality of life40-42 and increasing the use of
observation may avert the harms of unnecessary
biopsies43 and interventions2,3,6 while maintaining excellent long-term disease-specific survival.
In conclusion, our study showed that, as compared with observation, radical prostatectomy did
not significantly reduce all-cause or prostatecancer mortality through at least 12 years among
men with clinically localized prostate cancer that
had been diagnosed in the era of PSA testing.
Absolute differences in mortality between the
study groups were less than 3 percentage points.
Subgroup analyses suggested that surgery might
reduce mortality among men with higher PSA
values and possibly among men with higher-risk
tumors, but not among men with PSA levels of
10 ng per milliliter or less or among men with
low-risk tumors.
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